Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.79 |
| ▸ | ALPL | P05186 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Higenamine SCHEMBL5898913 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (+)-Higenamine SCHEMBL30464469 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL29365055 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL5898911 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL30105922 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL5898916 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL29374757 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (+)-Higenamine SCHEMBL5898932 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL28478764 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL29623874 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125725-A1 | Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof | ANTHEIA INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260121027-A1 | POSITIVE ELECTRODE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2026-04-30 | — | — | US | claimed |
| US-20260110656-A1 | ELECTROCHEMICAL SENSOR PREPARED FROM NIOBIUM CARBIDE-REDUCED GRAPHENE OXIDE AEROGEL COMPOSITE MATERIAL AND ITS UTILIZATION | NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY (TW) | 2026-04-23 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260074280-A1 | Rechargeable Lithium Batteries | SAMSUNG SDI CO LTD (KR) | 2026-03-12 | — | — | US | claimed |
| US-20250388939-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | RIVER STONE BIOTECH APS (DK) | 2025-12-25 | — | — | US | claimed |
| EP-4615963-A1 | GENETICALLY MODIFIED BENZYLISOQUINOLINE ALKALOID-PRODUCING HOST CELLS WITH MODIFIED EFFLUX TRANSPORTER GENE EXPRESSION | River Stone Biotech ApS (DK) | 2025-09-17 | — | — | EP | claimed |
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| US-12371722-B2 | Recombinant host cells with improved production of L-DOPA, dopamine, S-noroclaurine or derivatives thereof | RIVER STONE BIOTECH APS (DK) | 2025-07-29 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| EP-2376073-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | Zachar, Oron (IL) | 2011-10-19 | — | — | EP | claimed |
| WO-2011084459-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | claimed |
| WO-2011084456-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | claimed |
| CN-102107006-A | Coupling medicament for treating diabetes mellitus and medicinal application thereof | CHIFCON DRUG DISCOVERY SUZHOU INC | 2011-06-29 | — | — | CN | claimed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | claimed |
| US-20110144209-A1 | USE OF VASOCONSTRICTORS | ZACHAR ORON | 2011-06-16 | — | — | US | claimed |
| EP-2313037-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | Zachar, Oron (IL) | 2011-04-27 | — | — | EP | claimed |
| WO-2010063030-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | FEIGELSON, DANIEL (IL) | 2010-06-03 | — | — | WO | claimed |
| WO-2010001391-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | ZACHAR ORON (IL) | 2010-01-07 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260074280-A1 | Rechargeable Lithium Batteries | SLC9A2, SLC9A1, CACNA2D1 | DRD2 2499/4885DRD4 2396/4885KDM1A 1366/4885 |
| US-20260125725-A1 | Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof | OPRD1, OPRM1, OPRK1 | DRD2 218/4885DRD4 374/4885KDM1A 3075/4885 |
| US-20260110656-A1 | ELECTROCHEMICAL SENSOR PREPARED FROM NIOBIUM CARBIDE-REDUCED GRAPHENE OXIDE AEROGEL COMPOSITE MATERIAL AND ITS UTILIZATION | OGG1, SCO2, CPNE4 | DRD2 1615/4885DRD4 1008/4885KDM1A 2977/4885 |
| US-20260121027-A1 | POSITIVE ELECTRODE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME | CACNA2D4, SLC8A1, SLC9A2 | DRD2 2300/4885DRD4 1998/4885KDM1A 2536/4885 |
| US-20250388939-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | DBH, DDT, COMT | DRD2 989/4885DRD4 1463/4885KDM1A 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.